CRC Research Update — October 24, 2026
Today's colorectal cancer research highlights
kras-g12c
A collection of 41 issues
CRC Research Update — October 06, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 23, 2026
Today's colorectal cancer research highlights
Ifebemtinib Plus Garsorasib in KRAS G12C–Mutated Metastatic Colorectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Ifebemtinib Plus Garsorasib in KRAS G12C–Mutated Metastatic Colorectal Cancer
(Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
CRC Research Update — September 14, 2026
Today's colorectal cancer research highlights
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC
A matching-adjusted indirect comparison evaluated sotorasib combined with panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only
CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC
A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor
CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights